A Study to Evaluate GSK1325760A - a Long-Term Extension Study
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety of long-term administration of
GSK1325760A in patients with PAH.
The secondary objectives of this study are to evaluate long-term administration of
GSK1325760A on:
- Improvement in exercise capacity (six-minutes walk distance: 6MWD), change in WHO
Functional Classification and time to clinical worsening of PAH
- Change in the Borg Dyspnea Index (assessed immediately following the six-minute walk
test [6MWT])
- Change in plasma brain natriuretic peptide (BNP) levels
- Cardiopulmonary hemodynamics parameters (as measured by echocardiography)